These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28148677)

  • 21. [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].
    Kawamoto Y; Yoshino T
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():346-50. PubMed ID: 22213982
    [No Abstract]   [Full Text] [Related]  

  • 22. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sweeping KRAS generalizations: are we depriving patients of an effective treatment? A novel KRAS mutation and dramatic response to panitumumab in a patient with metastatic colorectal cancer.
    Zikria J; Krishnamoorthy S; Kaley K; Saif MW
    Int J Colorectal Dis; 2011 Oct; 26(10):1353-4. PubMed ID: 21229361
    [No Abstract]   [Full Text] [Related]  

  • 24. Epidermal growth factor receptor in CRC patients in the era of the RAS.
    Yanmaz MT; Demir G; Erdamar S; Keskin S; Aydin MF; Guner SI
    Hepatogastroenterology; 2015; 62(137):40-4. PubMed ID: 25911864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
    Alves S; Castro L; Fernandes MS; Francisco R; Castro P; Priault M; Chaves SR; Moyer MP; Oliveira C; Seruca R; Côrte-Real M; Sousa MJ; Preto A
    Oncotarget; 2015 Oct; 6(31):30787-802. PubMed ID: 26418750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition.
    Stites EC
    Methods Mol Biol; 2021; 2262():311-321. PubMed ID: 33977486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS mutations: analytical considerations.
    Herreros-Villanueva M; Chen CC; Yuan SS; Liu TC; Er TK
    Clin Chim Acta; 2014 Apr; 431():211-20. PubMed ID: 24534449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
    J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
    Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
    [No Abstract]   [Full Text] [Related]  

  • 31. The Cost and Value of Anti-Epidermal Growth Factor Receptor Therapies: Let's Not Be Rash.
    Saltz LB
    JAMA Oncol; 2015 May; 1(2):141-2. PubMed ID: 26181010
    [No Abstract]   [Full Text] [Related]  

  • 32. KRAS mutation status, comorbidity, and mortality in patients with metastatic colorectal cancer in Denmark.
    Ording AG; Öztürk B; Spindler KG; Sørensen HT; McCusker M; Ehrenstein V
    Acta Oncol; 2018 Dec; 57(12):1727-1729. PubMed ID: 30264648
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
    Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
    Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
    Bertagnolli MM
    J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
    [No Abstract]   [Full Text] [Related]  

  • 35. The Frequency and Type of K-RAS Mutations in Mexican Patients With Colorectal Cancer: A National Study.
    Cárdenas-Ramos SG; Alcázar-González G; Reyes-Cortés LM; Torres-Grimaldo AA; Calderón-Garcidueñas AL; Morales-Casas J; Flores-Sánchez P; De León-Escobedo R; Gómez-Díaz A; Moreno-Bringas C; Sánchez-Guillén J; Ramos-Salazar P; González-de León C; Barrera-Saldaña HA
    Am J Clin Oncol; 2017 Jun; 40(3):274-276. PubMed ID: 25333735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
    Russo M; Siravegna G; Blaszkowsky LS; Corti G; Crisafulli G; Ahronian LG; Mussolin B; Kwak EL; Buscarino M; Lazzari L; Valtorta E; Truini M; Jessop NA; Robinson HE; Hong TS; Mino-Kenudson M; Di Nicolantonio F; Thabet A; Sartore-Bianchi A; Siena S; Iafrate AJ; Bardelli A; Corcoran RB
    Cancer Discov; 2016 Feb; 6(2):147-153. PubMed ID: 26644315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status.
    Akman T; Oztop I; Baskin Y; Unek IT; Demir N; Ellidokuz H; Yilmaz AU
    J Cancer Res Ther; 2016; 12(1):96-102. PubMed ID: 27072218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
    Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
    Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
    [No Abstract]   [Full Text] [Related]  

  • 40. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.
    Jeantet M; Tougeron D; Tachon G; Cortes U; Archambaut C; Fromont G; Karayan-Tapon L
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.